Conclusion Long-term administration of VASOREL has favorable clinical tolerability and safety for CHD patients.
结论冠心病患者长期服用曲美他嗪的临床耐受性和安全性良好。
Results the trial was completed in 95% of the patients, 2 patients withdrew in the VASOREL group and 4 patients in the control group; but none for the intolerable therapy.
结果试验总完成率95%，其中治疗组2例、对照组4例脱落，无患者因不耐受药物而脱落。
Results the trial was completed in 95% of the patients, 2 patients withdrew in the VASOREL group and 4 patients in the control group; but none for the intolerable therapy.
结果试验总完成率95%，其中治疗组2例、对照组4例脱落，无患者因不耐受药物而脱落。
应用推荐